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R22 DOCOSAHEXAENOIC ACID (DHA) IN CYSTIC FIBROSIS
C. Agostoni. Department of Pediatrics, San Paolo Hospital, University of Milan,
Italy
An increased metabolic rate of Arachidonic Acid (C20:4n-6, AA) and its derivatives
(prostanoids: prostaglandins, leukotrienes, thromboxanes) has been suggested as
starting process of the biochemical and clinical derangements described in CF
patients. This process might lead, on one hand, to reduced pools of linoleic acid
(C18:2n-6, LA), the metabolic precursor of AA, and, on the other, to a continuous
sub-inﬂammatory status affecting several organs and increasing the energy demand
of patients. Within these processes, docosahexaenoic acid (C22:6n-3, DHA), the
main derivative from the parental alpha-linolenic acid (C18:3n-3, ALA), maybe also
reduced in CF as a secondary result of the sub-inﬂammatory status requiring high
rates of AA conversions to prostanoids. This biomechanism could indirectly increase
the consumption of DHA, whose role in hampering the metabolic conversions of
AA derivatives has been shown in experimental models. The characteristics of the
dietary treatment of CF patients could contribute to low DHA levels in blood and tis-
sues, as result of both a low supply coupled with an increased use for energy produc-
tion. Reduced levels of DHA in blood and tissue specimen have been observed in CF
patients, with the lowest levels found in those with the most severe CF genotypes. As
a consequence, the ratio of AA to DHA in blood and/or tissues has been proposed
as marker of disease (a higher value of the ratio corresponding to worst conditions).
Infants and children could be particularly exposed to the negative consequences of
a high AA, low DHA status, since they physiologically need both AA and DHA for
growth and development. Therefore, CF can be proposed as a model of increased
AA availability for inﬂammatory processes where DHA is consumed, and where
both these compounds are diverted from their biological and-points. The observed
positive effects of early breastfeeding on later markers of disease progression are
consistent with this hypothesis, since human milk represents a natural source of
DHA within a balanced mixture of long-chain polyunsaturated fatty acids. To sub-
stantiate this hypothesis, well-controlled clinical trials are needed to check whether
DHA supplementation, along with an adequate and balanced dietary regimen,
could restore the fatty acid status and the AA/DHA ratio, with positive effects on
functional markers of the disease, such as lung ventilatory measures and/or indices
of infections and morbidity as well as nutritional status, growth and development.
R23 TOWARDS A EUROPEAN CLINICAL TRIAL NETWORK
K. De Boeck. University Hospital Gasthuisberg, Leuven, Belgium
In the past decades, the prognosis of patients suffering from CF has been improved
considerably by means of a very intensive supportive therapeutic management.
However, in spite of all achievements, the life expectancy and especially the quality
of life of CF patients remains very limited compared to those of their healthy peers.
Thus, there is a considerable need to optimise the existing therapies and to develop
new treatment options. With the better understanding of the basic pathophysiology
of CF there is even hope that a curative treatment will be found.
For decades many committed CF centres have contributed greatly in clinical
research aimed at improving patient care. The added value of neonatal screening for
CF has also been documented. Thanks to meticulous follow-up and more intensive
treatment early on, in recent decades, the rate of deterioration of lung function is
slower and the current yearly drop in FEV1, the best surrogate outcome parameter,
is only around 1−2%. Only appropriately powered trials will bring CF clinical
research further. Increasingly large multi-centre trials will be the only option. For
this reason, ECFS wants to intensify the clinical research in the ﬁeld of CF in
terms of quality and quantity. In order to be able to offer the structures required
for a quick and professional implementation of clinical studies, the ECFS initiated
the foundation of the Clinical Trial Network (ECFS-CTN). The ECFS-CTN aims
to be a network in which interested CF trial sites, fulﬁlling criteria with regard to
quality of care as well as performance of clinical research, will voluntarily form
an alliance. The aim of forming the ECFS-CTN is the consistent performance and
successful completion of clinical studies in accordance with good clinical practice
guidelines. Innovative therapies could thus be available to CF patients more quickly.
The successful model of the American cystic ﬁbrosis foundation therapeutic
development network (CFF-TDN) will work inspiringly to develop the road map
for the emerging European clinical trial network.
R24 MONITORING OF ANTI-PSEUDOMONAS AERUGINOSA THERAPY
IN EARLY PHASES OF THE INFECTION
G. Taccetti, N. Ravenni, S. Campana. Cystic Fibrosis Center, Meyer Children’s
Hospital, Florence, Italy
Chronic colonization by Pseudomonas aeruginosa (Pa) is an unfavorable event in
the prognosis of cystic ﬁbrosis (CF) patients. In the absence of a cure for CF, preven-
tion of chronic colonization by eradicating the germ upon initial isolation appears
to be a simple and efﬁcacious way to improve long-term prognosis. The efﬁcacy of
eradication therapy, regardless of the type of drug used and duration of treatment,
is on average 75%. Patients colonized by Pa and treated immediately should
be monitored microbiologically, using molecular and immunological techniques.
Classical monitoring using growth cultures does not distinguish between regrowth
of suppressed but uneradicated strains and colonization by a new strain. Therefore,
genotyping of strains isolated in the ﬁrst and next colonization episodes should be
performed. In our experience, re-colonization by Pa following eradication therapy
is mainly caused by strains of different genotype, suggesting acquisition from an
external source. A short Pa-free period is mainly due to transient suppression of Pa
growth. True eradication followed by acquisition of a new Pa genotype occurs in
most cases only after a Pa-free period >6 months. Patients with a Pa-free interval of
<6 months had a 6-times higher chance that the Pa was not eradicated in comparison
with those with a germ-free interval of >6 months.
To improve results of bacteriological cultures, ampliﬁcation via PCR of a speciﬁc
gene fragment of Pa directly on respiratory samples was performed. This approach
identiﬁes a higher number of patients with Pa than conventional growth culture and
can supplement Pa identiﬁcation.
The potential use of immunological markers for monitoring eradication therapy has
been evaluated. There are several methods for investigating anti-Pa antibodies but
none of these can be considered a gold standard. Our research indicates that 45%
of patients have an increase of IgA anti-Pa antibodies before isolation of the germ.
A rise in antibody titers indicates probable infection and eradication treatment may
then be initiated, even in the absence of microbiological detection of Pa. In these
cases, growth cultures should be carried out at briefer intervals.
Monitoring of eradication treatment cannot rely only on microbiological evidence
but requires investigation of other potential markers as well.
R25 NEW DIAGNOSTIC AND THERAPEUTIC APPROACHES IN
CYSTIC FIBROSIS RELATED DIABETES (CFRD)
L. Minicucci. Genova CF Center, Genova, Italy
Diabetes is a frequent co-morbidity in cystic ﬁbrosis (CF). Although CFRD has
always been considered a mild form of diabetes mellitus (DM) with a low risk of
severe complication, it is associated with a worse prognosis in affected patients,
due to deﬁcient anabolizing action of insulin and, probably, to increased risk of
infections related to hyperglycemia. To date, the only accredited therapy of CFRD
is insulin, which is performed according to the therapeutic protocols used in Type 1
and Type 2 diabetic patients.
For a better management of CFRD condition a continuous and close collaboration
with the diabetologic consultant is mandatory, to import to CFRD patients the new
diagnostic and therapeutic approches in DM management. Research in the diabetic
ﬁeld has been developed in these last years, ranging from inhaled insulin to islet
transplantation, and from gene therapy to stem cells. However, these approches will
need to be formally tested in rigorous clinical trials before they can become part
of the daily lives of people with DM. Moreover, some of these new therapies, as
inhaled insulin, do not suit with the underlyng disease in CFRD patients. In our
opinion, up to date, CFRD caregivers, waiting for future better tools to manage the
problem, have to work, above all, on reducing negative impact that abnormal glucose
metabolism has on the CF patients’ future. New therapeutic protocols, studying
“when” and “what” to use in the condition of glucose abnormal metabolism in CF,
have to be implemented. An Italian multicenter randomized clinical trial about the
use of Glargine Insulin in CF patients, affected by glucose intolerance, is ending
the patients’ recruitment.
R26 CLINICAL IMPACT OF TOBI® ON CYSTIC FIBROSIS PATIENTS
WITH CHRONIC PSEUDOMONAS AERUGINOSA COLONISATION:
RESULT OF A POST-MARKETING SURVEILLANCE
J. Bua1, L. Ronfani1, C. Braggion2, F. Marchetti1. The Collaborative Group of
Italian Society for Cystic Fibrosis. 1Institute of Child Health, Burlo Garofolo,
Trieste, Italy; 2Cystic Fibrosis Unit, Meyer Hospital, Firenze, Italy
Aim: A number of studies have shown a beneﬁcial effect of nebulized antibiotics in
cystic ﬁbrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) infection.
We performed a post-marketing surveillance with the aim of comparing the clinical
outcome before and after starting TOBI in a CF population with chronic PA
colonization.
Methods: Our study is part of a larger post-marketing surveillance study which
involved 21 Italian Cystic Fibrosis Centres and included 603 patients using TOBI, of
whom 86 with ﬁrst PA infection and 517 with chronic PA colonisation. Spirometric,
clinical and therapeutical data were collected at 12 months before starting TOBI,
at TOBI start, and at 6 and 12 months after TOBI start.
Results: Out of 517 patients with chronic PA infection, 422 used TOBI for 12
months. Although the mean number of days of hospitalization and of intravenous
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(IV) antibiotic treatment did not change signiﬁcantly before and after 12 months of
TOBI, the number of oral antibiotic treatment days was reduced signiﬁcantly (27.2
vs 20.1; p< 0.001). Overall when comparing the mean predicted FEV1 before 12
months from TOBI start with that after 12 months, no signiﬁcant change was found.
Between the 12 months before and TOBI start, mean FEV1 showed a decrease of
3.5% of the predicted value (from 69.1% to 66.7%), while 6 months after TOBI
start, it increased to 68.3%. This increase was most apparent in patients of 13
to 18 years of age (from 74.5% to 78.6%). After the second other 6 months of
treatment, mean predicted FEV1 showed a slight decrease (−1.6%). During 12
months of follow-up, 12% of patients interrupted TOBI because of side effects
(mainly tinnitus, bronchospasm, dysphonia).
Conclusions: Our study showed that TOBI seems to stabilise the mean value
of predicted FEV1 after 12 months of treatment but does not increase it. TOBI
treatment did not have a signiﬁcant effect in reducing neither the days of IV
antibiotics nor those of hospitalisation, while it was associated with a decrease in
the length of oral antibiotic treatment. Post-marketing surveillance studies have an
important role in describing the effectiveness of treatment in the real non-controlled
clinical context.
R27 EARLY EVALUATION OF CF LUNG DISEASE
H.A.W.M. Tiddens. Department of Pediatric Pulmonology and Allergology,
Department of Radiology, ErasmusMC-Sophia Children’s Hospital, Rotterdam,
The Netherlands
CF patients have lung inﬂammation and infection beginning early in life. This leads
to an irreversible structural damage that is heterogenously distributed throughout the
lung. Adequate monitoring of CF lung disease is paramount to tailoring treatment to
a patient’s need. Pulmonary function tests are insensitive to detect localized or early
damage. Computed Tomography (CT) is the most sensitive tool to detect structural
abnormalities at an early stage of CF lung disease.
Important structural changes that can be detected at an early stage are airway wall
thickening, air trapping, bronchiectasis, and mucus plugging.
Chronic inﬂammation leads to airway wall thickening which is present in young
children with CF. This is more severe in peripheral than in central airways. On CT
peripheral airways cannot be observed directly because they are too small relative to
the CT resolution; they can be identiﬁed indirectly as hypodens areas on expiratory
chest CT representing air trapping areas often combined with hypoperfusion. Mucus
plugging and bronchiectasis are other important structural changes, the latter being
an irreversible and progressive widening of an airway becoming evident in the
majority of patients in childhood. The goldstandard to diagnose bronchiectasis is
through a volumetric CT scan taken at end-inspiration.
Monitoring with CT should start in infancy at regular time interval. Unfortunately,
there are some major hurdles to overcome in young children: (1) CT should only
be done in radiology departments with experience in using the lowest possible
radiation dose; (2) life long radiation exposure should be limited to acceptable
levels. Radiation dose has been brought down substantially in the last decade and
it is likely that it will be further reduced in the near future. A CT scan should
be done at end inspiration and end expiration during a breath hold; in children
younger than 4 yrs the procedure should be done under general anesthesia. This
requires a dedicated team with experience in using the controlled volume technique.
The risk of atelectasis can be avoided when the CT is made using a modern fast
scanner during spontaneous breathing that allow to do a whole CT scan in less
than 1 second. The sensitivity of this method to diagnose air trapping is probably
less compared to the controlled volume technique. In children older than 4 yrs it
is possible to do a whole lung in- and expiratory scan each during a breath hold.
Only few therapeutic studies in young children are available that included chest CT.
Hence, how to deal with abnormalities observed on CT scans of young children
is not straight forward. When the CT scan is normal the pulmonary condition is
probably good; if major abnormalities are being observed more aggressive therapy
should be considered.
R28 EUROPEAN CYSTIC FIBROSIS SOCIETY CONSENSUS ON
GENETIC TESTING
M. Schwarz, C. Castellani, H. Cuppens, Jr M. Macek, J.J. Cassiman, E. Kerem,
P. Durie, E. Tullis, B.M. Assael, C. Bombieri, A. Brown, T. Casals, M. Claustres,
G. Cutting, J. Dodge, I. Doull, P. Farrell, C. Ferec, E. Girodon, M. Johannesson,
B. Kerem, M. Knowles, A. Munck, P.F. Pignatti, D. Radojkovic, P. Rizzotti,
M. Stuhrman, M. Tzetis, J. Zielenski, J.S. Elborn
This paper describes the conclusions of a consensus conference to address the use
and interpretation of CF mutation analysis in the clinical setting.
The limitations of genotyping technology, the choice of mutations to be tested, the
clinical context in which the test is being taken can all inﬂuence how genetic
information is interpreted. Although the diagnosis of cystic ﬁbrosis is usually
straightforward, care needs to be exercised in the use and interpretation of genetic
tests; genotype information is not the ﬁnal arbiter of a clinical diagnosis of cystic
ﬁbrosis or cystic ﬁbrosis transmembrane regulator protein related disorders. The di-
agnosis of these conditions is primarily based on the clinical picture, and supported
by measurements of CFTR function (sweat testing, nasal potential difference and so
on) and genetic analysis. None of these is sufﬁcient on its own to make a diagnosis
of CF or CFTR related disorders.
The consensus addressed the prognostic value of particular genotypes and concluded
that, although useful in group studies, individual genotype can not accurately predict
the pulmonary outcomes in people with CF.
Genotype analysis is a very valuable tool in the diagnosis and assessment of people
with cystic ﬁbrosis and CFTR related disorders; the availability of relatively cheap
DNA sequencing of the entire CFTR gene has thrown up numerous novel mutations
and sequence variants but these must be interpreted with due acknowledgement of
the limitations of primary DNA sequence analysis.
Finally, and of paramount importance, good communication between clinicians and
medical genetic laboratories is vital. Information must be exchanged clearly and
completely between the laboratory and the clinician, and subsequently communi-
cated to the patient in an understandable way.
